非唑奈坦的用法用量

Fizolinant is the first non-hormonal drug approved by the FDA for the treatment of vasomotor symptoms of menopause. Its standard usage is 45 mg orally once daily. Proper medication administration is crucial to reducing adverse reactions. This article will introduce in detail the standard usage and dosage of fezonatant, possible side effects and medication precautions for special groups, providing a reference for clinical medication.

Usage and Dosage of Fezonatant

The medication regimen is relatively fixed, but special attention should be paid to the medication time, method and related liver function monitoring requirements, and medication should be taken strictly under the guidance of a doctor.

Standard dosage regimen

The recommended dose is a 45 mg tablet taken orally once daily, with or without food. Tablets should be swallowed whole and not cut, crushed or chewed. It is recommended to take the medicine at a fixed time every day to maintain a stable blood concentration.

Principles for handling missed doses

If the missed dose does not exceed 12 hours, you should take it immediately; if it has exceeded 12 hours, skip the dose and take the next dose as originally planned. Do not double the dose to make up for a missed dose.

Liver function monitoring requirements

Baseline liver function tests (ALT, AST, ALP and bilirubin) must be performed before taking the drug. Liver function needs to be reviewed 3, 6, and 9 months after the start of treatment. If ALT or AST ≥ 2 times ULN or total bilirubin ≥ 2 times ULN, initiation of treatment should be prohibited.

Strictly adhering to the medication specifications of Fezonastat is the basis for ensuring the therapeutic effect and at the same time minimizing the risk of adverse reactions.

Side effects of filzonitant

The spectrum of adverse reactions of filzonitant is relatively clear, and understanding these reactions can help with early identification and appropriate treatment.

Common adverse reactions

Mainly include abdominal pain, diarrhea, insomnia, back pain and hot flashes. These symptoms are mostly mild to moderate and usually appear in the early stages of medication, and most patients can gradually tolerate it.

Liver-related adverse reactions

Elevated liver transaminase is the most vigilant adverse reaction, and patients have ALT/AST ≥ 3 times ULN. If symptoms such as fatigue, loss of appetite, and jaundice occur, you should stop taking the medicine immediately and seek medical advice.

Other system reactions

A few patients reported neurological symptoms such as headache and dizziness. Digestive system reactions such as nausea and vomiting have also been reported, but the incidence is relatively low.

Most of the side effects of fezonatant are controllable, and timely identification and treatment can significantly improve medication safety.

Special population use of fezonatant

Different populations have different metabolism and tolerance of fezonatant, and the medication regimen needs to be adjusted individually.

Patients with hepatic and renal insufficiency

Patients with Child-Pugh Class A/B liver damage should use it with caution, and it is contraindicated in patients with liver cirrhosis. It is prohibited to be used by patients with severe renal impairment (eGFR<30ml/min) or end-stage renal disease.

Pregnant and lactating women

Data on use in pregnant women are limited, and use should only be considered when the potential benefits outweigh the risks. Breastfeeding women should weigh the risks and benefits; it is not known whether the drug is excreted in breast milk.

Elderly patients

The medication data for elderly patients over 65 years old are limited and do not require routine dose adjustment, but adverse reactions need to be closely monitored.

Special groups need to be extremely cautious when using fezonatant, and the benefit-risk ratio should be assessed based on individual circumstances before deciding on a treatment plan.